参附注射液辅助治疗急性心衰的效果及对TIMP-1、MMP-3的影响  

Effect of Shenfu Injection in auxiliary treatment of acute heart failure and its influence on tissue inhibitor of metalloproteinase-1, matrix metal-loproteinases-3

作　　者：何志红[1] 

机构地区：[1]广东省佛山市南海区中医院急诊科,广东佛山528200

出　　处：《中国医药导报》2016年第31期105-108,共4页China Medical Herald

基　　金：广东省佛山市卫生局医学科研课题立项管理项目(262)

摘　　要：目的探讨参附注射液辅助治疗急性心衰的临床效果,及其对血清组织金属蛋白酶抑制物-1（TIMP-1）、基质金属蛋白酶-3（MMP-3）的影响。方法选择2014年6月~2015年6月广东省佛山市南海区中医院收治的急性心衰患者90例,将其随机分为研究组和对照组,两组均进行消除病因、强心利尿、扩张血管、吸氧等常规治疗,研究组在此基础上加用参附注射液治疗,两组均治疗7 d。比较两组临床疗效,观察两组患者治疗前后收缩压（SBP）、舒张压（DBP）、左室射血分数（LVEF）的变化情况,采用酶联免疫吸附测定（ELISA）检测治疗前后TIMP-1、MMP-3水平。结果研究组总有效率明显高于对照组（P〈0.05）。治疗后两组患者SBP、DBP均较治疗前降低,LVEF较治疗前升高,且研究组治疗后SBP、DBP明显低于对照组,LVEF明显高于对照组,差异均有统计学意义（P〈0.05）。治疗后研究组血清TIMP-1水平高于对照组,MMP-3水平低于对照组,差异均有统计学意义（P〈0.05）。结论急性心衰患者在常规治疗的基础上加用参附注射液辅助治疗,可提高疗效,改善心功能,减少MMP3表达,促进TIMP-1表达,延缓心肌重构,值得临床推广。Objective To study the clinical effect of Shenfu Injection in auxiliary treatment of acute heart failure and its influence on serum tissue inhibitor of metalloproteinase-1（TIMP-1）, matrix metalloproteinases-3（MMP-3）. Methods Ninety cases of patients with acute heart failure admitted to Nanhai TCM Hospital of Foshan City from June 2014 to Jun 2015 were selected, and they were randomly divided into research group and control group. Both groups were given conventional treatment, such as eliminating the cause of disease, inotropic support and diuretic therapy, dilate blood vessels, oxygen inhalation, on the basis of conventional treatment, the patients in research group were given Shenfu Injection for auxiliary treatment, both groups were treated for 7 d. The clinical curative effects of the two groups were compared. Before and after treatment, the changes of systolic blood pressure（SBP）, diastolic blood pressure（DBP）, left ventricular ejection fraction（LVEF） in the two groups were observed, and the levels of TIMP-1, MMP-3 were detected by enzyme-linked immunosorbent assay（ELISA）. Results The total effective rate of research group was significantly higher than that of control group（P〈0.05）. After treatment, SBP, DBP of the two groups were reduced, the LVEF was increased, and SBP, DBP of research group were significantly lower than those of control group, LVEF was significantly higher than that of control group, the differences between the two groups were statistically significant（P〈0.05）. After treatment, the serum levels of TIMP-1 of research group was higher than that of control group, the level of MMP-3 was lower than that of control group, the differences were statistically significant（P〈0.05）. Conclusion On the basis of conventional treatment, Shenfu Injection adjuvant therapy in treatment of patients with acute heart failure can enhance the treatment effect, improve cardiac function, reduce the expression of MMP3, promote the expression of TIMP-1, delay myocardial remod

关 键 词：急性心衰 参附注射液 组织金属蛋白酶抑制物-1 基质金属蛋白酶-3 

分 类 号：R541.61[医药卫生—心血管疾病]